Literature DB >> 28742409

The effects of vitamin D and evening primrose oil co-supplementation on lipid profiles and biomarkers of oxidative stress in vitamin D-deficient women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.

Khadijeh Nasri1, Sedighe Akrami1, Maryam Rahimi2, Mohsen Taghizadeh3, Masoud Behfar3, Mohammad Reza Mazandaranian3, Abbas Kheiry3, Mohammad Reza Memarzadeh4, Zatollah Asemi3.   

Abstract

PURPOSE OF THE STUDY: There was inconsistent evidence about the benefit of vitamin D plus evening primrose oil (EPO) supplement intake on lipid profiles and reduced oxidative stress among women with polycystic ovary syndrome (PCOS). The current study was performed to evaluate the effects of vitamin D plus EPO supplementation on lipid profiles and biomarkers of oxidative stress in vitamin D-deficient women with PCOS.
MATERIALS AND METHODS: This randomized, double-blind, placebo-controlled trial was performed among 60 vitamin D-deficient women with PCOS. Participants were randomly assigned into two groups to receive either 1000 IU vitamin D3 plus 1000 mg EPO (n = 30) or placebo (n = 30) for 12 weeks. Metabolic profiles were quantified at baseline and after the 12-week intervention.
RESULTS: Compared with the placebo group, women in vitamin D and EPO co-supplementation group had significant increases in serum 25-hydroxyvitamin D (25(OH)D) (+10.7 ± 8.4 vs. -0.5 ± 1.6 ng/mL, p < 0.001) and plasma total glutathione (GSH) (+62.7 ± 58.0 vs. -0.7 ± 122.7 µmol/L, p = 0.01), while there were significant decreases in triglycerides (-7.3 ± 23.8 vs. +6.9 ± 26.3 mg/dL, p = 0.03), very low-density lipoprotein (VLDL) cholesterol levels (-1.5 ± 4.7 vs. +1.4 ± 5.3 mg/dL, p = 0.03), total/high-density lipoprotein cholesterol ratio (-0.3 ± 0.4 vs. -0.02 ± 0.4, p = 0.02), and malondialdehyde (MDA) concentration (-0.4 ± 0.4 vs. +0.5 ± 1.8 µmol/L, p = 0.008).
CONCLUSION: Overall, vitamin D and EPO co-supplementation for 12 weeks among vitamin D-deficient women with PCOS significantly improved triglycerides, VLDL cholesterol, GSH, and MDA levels.

Entities:  

Keywords:  Lipid profiles; oxidative stress; polycystic ovary syndrome; supplementation

Mesh:

Substances:

Year:  2017        PMID: 28742409     DOI: 10.1080/07435800.2017.1346661

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  4 in total

1.  Phytochemical and Biological Screening of Oenothera Biennis L. Hydroalcoholic Extract.

Authors:  Ramona Fecker; Valentina Buda; Ersilia Alexa; Stefana Avram; Ioana Zinuca Pavel; Delia Muntean; Ileana Cocan; Claudia Watz; Daliana Minda; Cristina Adriana Dehelean; Codruta Soica; Corina Danciu
Journal:  Biomolecules       Date:  2020-05-26

2.  Vitamin D supplementation prior to in vitro fertilisation in women with polycystic ovary syndrome: a protocol of a multicentre randomised, double-blind, placebo-controlled clinical trial.

Authors:  Kai-Lun Hu; Kwanghann Gan; Rui Wang; Wentao Li; Qiongfang Wu; Beihong Zheng; Libo Zou; Su Zhang; Yifeng Liu; Yiqing Wu; Ruixue Chen; Wushuang Cao; Shuo Yang; Fen-Ting Liu; Lifeng Tian; Han Zeng; Huiling Xu; Shumin Qiu; Lihua Yang; Xiao Chen; Xiaoqin Pan; Xiaoyun Wu; Ben W Mol; Rong Li; Dan Zhang
Journal:  BMJ Open       Date:  2020-12-08       Impact factor: 2.692

3.  The role of cholecalciferol deficiency in the pathogenesis of polycystic ovary syndrome.

Authors:  Aigul Safi; Mekan Orazov; Svetlana Kalinchenko
Journal:  Womens Health (Lond)       Date:  2020 Jan-Dec

4.  Effects of vitamin D supplementation on serum lipid profile in women with polycystic ovary syndrome: A protocol for a systematic review and meta-analysis.

Authors:  Xiao-Yan Shi; Jia Yao; Si-Min Fan; Pei-Pei Hong; Yu-Guo Xia; Qiu Chen
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.